• Record cash receipts from customers over last 12 months of $14.9M
• Major cost efficiency program completed with $1.1M in annual savings
• Two major clinical trials progressing to schedule, with $12M remaining to be invoiced

Resonance Health Ltd (ASX: RHT) has released its Appendix 4C and Quarterly Activities & Cashflow Report for the quarter ended 31 March 2025. The company continues to rapidly and profitably scale up its operations, with record cash receipts from customers over the last 12 months of $14.9M and positive cashflow from operations of $3.1M. The company completed a major cost efficiency program in March 2025, removing 12 roles and expecting annual savings of approximately $1.1M going forward. Resonance's three business focus areas - Clinical Trial Management CRO Services, Software-as-a-Medical Device Image Analysis Services, and Clinical Trial Site Services - all showed strong progress. The company's two major clinical trials, worth a combined $21.8M, are progressing to schedule, with approximately $8M invoiced to date and a further $12M remaining to be invoiced over the next 18 months. The SaMD business secured several contract extensions and new tenders worth over $3.5M, while the TrialsWest business is expected to record strong growth in FY26 due to new contracts and the second trial site opening. The company ended the quarter with a strong balance sheet, including $3.2M in cash and net cash of $0.3M.